{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-038564","form_type":"8-K","ticker":"DXR","cik":"0000027367","company_name":"DAXOR CORP","filed_at":"2023-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.592369+00:00","generated_at":"2026-06-09T07:27:06.411676+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Daxor allocates $1.9M of May 2023 offering proceeds to optical blood volume analyzer development","bullets":["Net proceeds of $3,555,532 from 410,260 shares at $9.75/share in May 2023 public offering.","$1,900,000 reserved for next-generation optical blood volume analyzer systems development.","Development expected over 24 months in conjunction with Department of Defense technology efforts."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-038564","json":"https://secwatch.observer/filing/0001493152-23-038564.json","markdown":"https://secwatch.observer/filing/0001493152-23-038564.md","text":"https://secwatch.observer/filing/0001493152-23-038564.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/27367/000149315223038564/0001493152-23-038564-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/27367/000149315223038564/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T07:27:06.411676+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}